Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.20p -2.45% 47.80p 90,320 16:35:20
Bid Price Offer Price High Price Low Price Open Price
47.00p 48.00p 49.00p 47.50p 49.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.5 -7.4 -8.7 - 55.97

Angle (AGL) Latest News

More Angle News
Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
16/3/201720:00ANGLE [12.75p] TARA*S SHARE OF THE DECADE "TARGET PRICE Ј100.00 PER SHARE."3,646
08/10/201611:43Angle PLC 201130,115
02/12/201513:04Angle 2016 – Liquid Biopsy Takeover Target-

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-03-19 16:35:2047.802,1781,041.08UT
2018-03-19 16:18:0347.507,5003,562.50O
2018-03-19 15:47:2547.30250118.25O
2018-03-19 14:40:4047.301,513715.65O
2018-03-19 14:24:1247.302,1751,028.78O
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 49p.
Angle Plc has a 4 week average price of 47.50p and a 12 week average price of 42.50p.
The 1 year high share price is 80p while the 1 year low share price is currently 32.25p.
There are currently 117,086,522 shares in issue and the average daily traded volume is 99,263 shares. The market capitalisation of Angle Plc is £55,967,357.52.
jelenko: I suspect there is an order to fill. As soon as it's filled it normally drops back a touch. Although, we are not too far from the MD Anderson lead Clinical Trial results(June/July), a few months which for longer term holders feels like days/weeks. I think we have good reason to expect positive results and Abbot piggybacking with HER2 evaluation it is likely to be a major turning point for AGL. The share price has not moved in step with the positive news flow over the last 12 months and it is fair to say that the company is still under the radar of most investors. I am personally expecting a gradual movement upwards as we get closer to June/July. It's quite difficult to predict what the share price may be in the future. I would be disappointed though if we do not challenge £1 on trial results rns. and £2.50 by the time of FDA approval.
jelenko: The whole markets are spooked. meanwhile AGL carry on with business, In my view the fact that we know when the clinical trial is likely to be completed allied to the fact that we know Parsortix does what it is claimed to do gives a high probability of FDA approval either DEC 18 or Jan 19 at the very latest. The fact that this whole Clinical trial process has been designed to satisfy the FDA and the fact that the FDA told AGL to do the Breast cancer trial first gives me great confidence. I don't have a clue what the share price will be on FDA approval but I suggest it will be higher than 50p A great deal depends on how quickly they can commercialise post FDA. From the recent Abbott link up I suspect very quickly. My point is that the American investors love revenue (don't mention profit, they don't worry about that!) Exact Sciences is our only benchmark really. Their mkt cap has been $6b yes billion. They have one colorectal product(cologard) and are lab based. It is very hard to imagine AGL reaching those sorts of numbers as an AIM stock. But FDA approval followed by a full NAzdaq listing or take over approach and who knows. I am certainly more confident that we are in the tunnel and have just spotted the light! The MM's will take advantage of the spread but in the scheme of things a few pence doesn't matter if next year we are talking £££;'s
chippyfriday: So, there is a great deal going on here with plans for FDA applications for ovarian and prostate cancer (and other cancers) following breast cancer approval. Also discussions with other companies in all relevant fields so could be news there at any time. The acquisition of Axela seems to be a good fit and a bargain at £3.6m given that the technology cost £25m to develop. Let’s hope that Angle isn’t sold on similar terms!!! “Whilst the enrolment of patients and analysis of results are conducted by independent cancer centres and outside the control of the Company, both the clinical study and the associated analytical studies are expected to complete in H2 CY 2018. This is intended to allow a full FDA submission promptly after the completion of the studies, once all the analysis and necessary submission documentation have been completed. Following the submission, the timing of FDA clearance will be driven by the de novo submission evaluation process within the FDA. The aim is for the Parsortix system to be the first ever FDA cleared system for harvesting cancer cells from blood for subsequent analyses. Once the breast cancer FDA clearance has been obtained, it is intended to extend it to other cancer types and applications, progressively, including ovarian and prostate cancer applications. Subsequent clearances will be less onerous to obtain as they will be based on an already cleared platform. Large scale deployment of the Parsortix system across numerous cancer types and application areas requires ANGLE to partner with large, global healthcare companies to take advantage of their distribution and sales channels and economic resources. Discussions are ongoing with companies in relevant fields: medtech companies, pharma companies, contract research organisations and reference laboratories (laboratories offering clinical tests). During the half year and post period end, two partnerships were signed with such healthcare companies”. Angle is my biggest holding, I’m not going to sell any and I will probably buy a few more on any weakness. It seems the big news to move the share price is still FDA approval but collaborations and continued research publications will hopefully allow the share price to make some progress.
glasswala: Read in city am today that US companies looking to snap up good biotech companies at knock down prices. Could this be the reason our share price is a fraction of the price of similar peer companies and has been manipulated down for a swoop by one of these US vultures. It's not like it will be the first time that a company's price has been held down for some unscrupulous fund to profit at the expense of the LTH who have funded the company with all the money and not seeing any profit for their trouble.
alloa2003: Its that time of year - what are your predicitons for the AGL share price in 12 months? I will start at £2 a share :)
willfy: Do you remember a few yrs ago, at Xmas share price was 85p, and we had a competition to forecast a yr on...Sadly we were all miles away, share price was about 40p ish year later, think we were all still naive then in our expectations, though to be fair I don't think any of us had invested in a medical co before, hence no idea of the timescale involved.Like to think we're all wiser, and hopefully by this time next yr, considerably richer...Have a feeling a lot of the long term shareholders who bailed out will be rather miffed at what they could have earned...
sicilian_kan: No miavoce I'm not suggesting that. That would be crazy to think. But companies have a degree of control over the release of news. E.g. when to sign the contract etc. They also have much greater control over when to time a placing and can time it around newsflow. So the two can go hand in hand and often do. Newland's problem is that he has left it far, far too late. I expect he initially would have preferred to place after the ovarian results, expecting the share price to rise, and then it didn't. Instead, the share price more than halved from its high. It kept on falling and was volatile. I doubt very much that this would have happened if Angle was well funded, which it is not. The market has driven the price down expecting funding needs and given the vagaries of the ovarian RNS with its claims of "up to 95%", which without more information as to what "up to" means is fairly useless. In summary, any fundraising in the 30p region will be a total failure. It will be raising funds at a near 5 year low, despite all the scientific progress. If you want any indictment on Newland, if he does place in the 30p region, that will be all the evidence you need to show his failings as a CEO. What Newland does is to head down incorrect paths (FDA approval), announcing unrealistic timetables (e.g. the repeated delays to ovarian), whilst looking after number one (i.e. himself) over and above the best interests of the company shareholders (his share sales and buybacks, accepting his far too high bonuses etc). For me, Newland has lost credibility. I just cannot rely upon his statements about timings etc. There are only so many times the pudding can (looking retrospectively) be overegged, however inadvertently. Of course, I accept that Angle has made massive progress scientifically and the company is a lot further ahead, but the share price is categorically in a bad, bad place. Many shareholders will be in a position of a loss and the potential dilution here will be significant. Yes, a deal or some other funding arrangement might come along that will be much better than a placing at these levels and could obviate the need for significant dilution. But given where the share price is, the market does not believe that this will be the case. The market may be wrong of course, but usually it is correct at times such as this one.
bones698: Steve et al , I have been posting on this board for more than 6 years although less frequently in the past . As things have deteriorated and reading the utter garbage some of the bulls post I have posted more frequently . The fact they are trying to call my motives and statements into question with absolutely zero facts to back up their claims is comical. I can see very few have bothered to look back at my posts which have predicted the demise of agls fortunes . Try all you like but the simple fact is the management have messed up, they are running out of cash fast and raise funds and the share price is taking because they have been far to slow to react to the situation . The market see doubts and lack.of funds and have trashed the share price knowing what is to come. Sad to see So many stale bulls completely blinded by their hopes rather than seeing the situation forwhat it is. Its not my fault your losing money and it's quite amusing to see the usual attacks on anyone posting negative comments just because you messed up thinking agl would be successful . Steve I suggest you read escapes posts again , he is calling the bulls not the bears like me idiot . Call my pigeon English like but appears many bulls can't even read lmao
willfy: It takes time to get a new broker in place, so possibly after the Ovarian results were out, and the share price started its long drift, the board acted swiftly in appointing fincap.Honestly do not believe the share price will be at this level by end of October, can you imagine attending the AGM if the share price were at 25 p ?Fully expecting a partial re-rating of some sought, and hopefully substantial news as well.
alloa2003: Personally I think if AGL had taken this slowly slowly approach a couple of years ago the share price would be much higher. We have suffered from mismanagement of expectations but hopefully the BOD have learnt a lesson. Let the results come through and let them speak for themselves. Trying to guess when the FDA might act on AGL's application(s) is a waste of time but good trial results will put more pressure on the FDA. Share price targets of £5 are unrealistic at this moment in time but we could have a game changing year and a rejuvenated share price. First of all we need to see constant positive news flow and better management of expectations. The recent research note suggesting a share price of 187p (from memory) seems ambitious but achievable in this very volatile area in which AGL operates. One of the other keys is to maximise the current benefits of Parsortix over competing system asap - that way we get a foothold in the market. Once we are there, the companies who operate in this area will not be changing their systems every 2 minutes and only then will we see the sales flow that everyone has been hoping for.
Angle share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20180320 04:11:28